analytics_image
\
Vantage Market Research
Vantage Market Research

Reports - Monoclonal Antibodies Market

iconHealthcare

Monoclonal Antibodies Market

Monoclonal Antibodies Market Size Analysis Report 2025-2035 by Source (Murine, Chimeric, Humanized, Human) by Indication (Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Others) by End User (Hospitals, Research Institutes, Others) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa

ppt icon
pdf icon
xlsx icon
power bi icon
immediate delivery icon

Industry Leaders Trust Us For Actionable Intelligence

Revenue Insights

Market Size in 2024

USD 263.22 Billion

Market Size By 2035

USD 1082.5 Billion

CAGR (2025 - 2035)

13.75%

Largest Region

North America

Fastest Region

Asia Pacific

Base Year

2024

Historic Data

2021 - 2023

Forecast Period

2025 - 2035

Segments Covered

By Source, By Indication, By End User, By Region

Report Coverage

The final deliverable will encompass both quantitative and qualitative data, providing a comprehensive analysis of the market. The scope is customizable.

Overview

Global Monoclonal Antibodies Market:

Monoclonal Antibodies Market - By Source, Indication, End User, and Region.

Monoclonal Antibodies Market Size, 2024 To 2035 (USD Billion)

Market Synopsis:

The global Monoclonal Antibodies Market is valued at USD 263.22 Billion in 2024 and is projected to reach a value of USD 1082.5 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 13.75% between 2025 and 2035.

Monoclonal Antibodies are used widely in immunotherapy where they attach mono to specific proteins and cells. They are replicas of identical immune cells and are derived from parental cells. They bond to antigens as they have a monovalent affinity while administered. Increasing focus on healthcare is anticipated to bolster demand for Monoclonal Antibodies across the forecast period. Increasing investments in genomic research and development are projected to further bolster Monoclonal Antibodies Market growth through 2028.

Rising incidences of cancer, high demand for biologics, rising use of next-generation sequencing, and increasing investment in genetic engineering technologies are projected to be major factors that drive the Monoclonal Antibodies Market potential over the coming years. However, lack of awareness and absence of developed healthcare infrastructure is predicted to hinder the overall Monoclonal Antibodies Market growth over the forecast period. The growth of the Monoclonal Antibodies Market in developing economies is expected to be slower than in developed countries. Supportive government initiatives and favorable reimbursement policies are projected to bolster Monoclonal Antibodies Market potential.

Market Segmentation:

The Monoclonal Antibodies Market is segmented based on Source, Indication, and End User and Region. Based on the End-User the market is segmented into Hospitals, Research Institutes, and Others. Based on the Source, the market is segmented as Murine, Chimeric, Humanized, and Human. Based on Indication, the market is segmented as Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, and Others.

Based on the End-User:

Based on End User segment, the market is segmented as Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, and Others. The Cancer sub-segment accounts for a major market share owing to the increasing prevalence of cancer across the world. Increasing investments in cancer treatment development are expected to bolster Monoclonal Antibodies demand on a global scale. Rising investments in Research and Development (R&D) of novel drugs is also expected to boost Monoclonal Antibodies demand.

Based on Source:

Based on the Source, the market is sub segmented into Murine, Chimeric, Humanized, and Human. The Human sub-segment is anticipated account for a dominant market share over the forecast period. Integration of advanced technologies and rising demand for Human Monoclonal Antibodies generation are prominent factors that drive the growth in the overall Monoclonal Antibodies Market across the world. Increasing demand for novel diagnostic and treatment procedures, rising prevalence of chronic diseases, and technological advancements in genomics are other factors that bolster growth in the overall Monoclonal Antibodies Market.

North America Accounts for a Dominant Market Share

The market for Monoclonal Antibodies in North America is projected to account for a significant market share owing to high investments in healthcare infrastructure. The increasing prevalence of cancer in this region is projected to boost demand for Monoclonal Antibodies through 2028. The presence of developed healthcare infrastructure and increasing investments in research and development of novel treatment and treatment drugs are projected to further boost Monoclonal Antibodies Market potential over the coming years. The Monoclonal Antibodies Market in North America accounted for a market share of 37.9% in 2021 and held a net worth of USD 39.8 billion in the same year. The Asia Pacific is projected to witness the fastest increase in demand for Monoclonal Antibodies as the incidence of cancer increases in the region. Supportive government initiatives are also expected to propel Monoclonal Antibodies Market potential through 2028.

Competitive Landscape:

The key players in the Global Monoclonal Antibodies Market include- Abbott Laboratories and others.

Segmentation of the Global Monoclonal Antibodies Market:

Market Segmentation

ParameterDetails
Segment Covered

By Source

  • Murine
  • Chimeric
  • Humanized
  • Human

By Indication

  • Cancer
  • Autoimmune Diseases
  • Inflammatory Diseases
  • Infectious Diseases
  • Others

By End User

  • Hospitals (59.6%)
  • Research Institutes (27.5%)
  • Others (12.9%)

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Nordic Countries, Benelux Union, Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, South-East Asia, Rest of Asia Pacific)
  • Latin America (Brazil, Argentina, Rest of Latin America)
  • Middle East & Africa
Companies Covered
  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis
  • Pfizer
Customization ScopeEnjoy complimentary report customization—equivalent to up to 8 analyst working days—with your purchase. Customizations may include additions or modifications to country, regional, or segment-level data.
Pricing and purchase optionsAccess flexible purchase options tailored to your specific research requirements. Explore purchase options

Report coverage & Deliverables

Our PDF Reports And Online Dashboard
Will Help You Stay Ahead In The Market.

    Key features include:

  • Check
    Competitive benchmarking
  • Check
    Historical data and future forecasts
  • Check
    Company-wise revenue breakdown
  • Check
    Regional growth opportunities
  • Check
    Latest market trends and dynamics
  • Check
    Impact of emerging technologies like AI and automation
  • Check
    Key regulatory updates and ESG considerations

FAQ‘s

Related Reports

vantage logo

Vantage Market Research & Consultancy Services is all about providing accurate and reliable market intelligence to its clients for the seamless execution of their business growth strategies.

© 2025 Vantage Market Research. All right reserved
Secured Bysecured by
Monoclonal Antibodies Market Size Analysis Report 2025-2035